Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics Board Approves $3M Stock Repurchase Program

NEW YORK (GenomeWeb News) - Strategic Diagnostics said today that its board of directors has approved a program to repurchase up to $3 million of the company's outstanding shares of common stock over the next 12 months.
 
"We believe that our stock price does not reflect our belief in the long term value of Strategic Diagnostics,” Francis DiNuzzo, president and CEO, said in a statement. “A repurchase program will benefit SDI's shareholders and demonstrates our board's and management team's confidence in our business.”
 
The company’s shares have plummeted more than 80 percent over the last 12 months, reaching a 52-week low of $1.09 on Oct. 15. In mid-afternoon trading today, shares were up $4.5 percent to $1.39.
 
Strategic Diagnostics said the stock repurchase program will be funded with working capital. The company has cash, cash equivalents, and marketable securities of approximately $11 million and approximately 20.4 million shares of common stock outstanding.
 
The repurchases may be made on the open market, in block trades, or otherwise, and the program may be suspended or discontinued at any time, the company said.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.